Johnson & Johnson, Eli Lilly, Sandoz, and Teva are key market players, with a news release issued from Austin, TX.
2 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson, Eli Lilly, Sandoz, and Teva are key market players, with a news release issued from Austin, TX.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Sandoz and Liquidia Corp signed a promotion agreement for treprostinil injection.Sub-event
- J&J faces patent challenges and competitive pressure from biosimilars launched by Amgen and Teva, compounded by new price setting requirements under the Inflation Reduction Act.Sub-event
Four pharmaceutical companies are noted as key market players, with a news release from Austin.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Eli Lilly and Company
American pharmaceutical company
-
Sandoz
organization
Nothing else this week.
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.
- Eli Lilly outperformed Johnson & Johnson stock over the past year.
Coverage
Newest first; wire copies grouped- GlobeNewswire[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentat
- ZacksTime to Buy Eli Lilly and Other Undervalued Healthcare Stocks? Healthcare has been one of the toughest sectors for investors over the past year. In fact, over the last 12 months, it has been the wors